• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Graft vs. Host Disease (GvHD) - Articles and news items

EU approval in sight as Bellicum’s BPX-501 granted orphan drug designation

Industry news / 5 August 2016 / Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, a clinical stage biopharmaceutical company, has been granted orphan drug designations for both its T-cell therapy product candidate BPX-501 for treatment in hematopoietic stem cell transplantation (HSCT), and for activator agent rimiducid…

Tiziana announces development plans for foralumab

Industry news / 11 January 2016 / Victoria White

The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis…